Table 1 Baseline characteristics of mCRC patients
From: Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
Characteristic | n | % |
|---|---|---|
Total number | 118 | 100 |
Gender | ||
Male | 80 | 68 |
Female | 38 | 32 |
Primary tumour | ||
Colon | 82 | 70 |
Rectum | 36 | 30 |
Ethnic origin | ||
Caucasian | 114 | 96 |
Asian | 2 | 2 |
Others | 2 | 2 |
ECOG performance status | ||
0 | 50 | 42 |
1 | 52 | 44 |
2 | 14 | 12 |
Prior adjuvant chemotherapy | ||
Yes | 83 | 70 |
No | 35 | 30 |
Carcinoembryonic antigen (μg l-1) | 17 | |
Median (range) | (0–12, 900) | |
